Oxidative Stress Regulates Expression of VEGFR1 in Myeloid Cells: Link to Tumor-Induced Immune Suppression in Renal Cell Carcinoma
Open Access
- 1 July 2008
- journal article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 181 (1) , 346-353
- https://doi.org/10.4049/jimmunol.181.1.346
Abstract
Metastatic renal cell carcinoma (RCC) associates with overproduction of vascular endothelial growth factor (VEGF) due to the mutation/inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene. Herein we demonstrate that implantation of human RCC tumor cells into athymic nude mice promotes the appearance of VEGF receptor 1 (VEGFR1)/CD11b double-positive myeloid cells in peripheral blood. Avastin-mediated VEGF neutralization was capable of significantly reducing the numbers of circulating VEGFR1+ myeloid cells. Conversely, up-regulation of VEGFR1 by myeloid cells could also be achieved in vitro by coculturing bone marrow cells with RCC-conditioned medium or by short-term exposure of naive myeloid cells to oxidative stress. Treatment of myeloid cells with H2O2, lipid peroxidation product 4-hydroxy-2(E)-nonenal, or an inhibitor of thioredoxin reductase all resulted in increased expression of VEGFR1. Furthermore, after exposure to oxidative stress, myeloid cells acquire immunosuppressive features and become capable of inhibiting T cell proliferation. Data suggest that tumor-induced oxidative stress may promote both VEGFR1 up-regulation and immunosuppressive function in bone marrow-derived myeloid cells. Analysis of tumor tissue and peripheral blood from patients with metastatic RCC revealed that VEGFR1+ cells can be also found in cancer patients. Restoration of immunocompetence in metastatic RCC patients by pharmacological elimination of VEGFR1+ cells may have a significant impact on the therapeutic efficacy of cancer vaccines or other immune-based therapies.Keywords
This publication has 36 references indexed in Scilit:
- Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cellsNature Biotechnology, 2007
- Reversal of Tumor-Mediated ImmunosuppressionClinical Cancer Research, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancerCancer and Metastasis Reviews, 2006
- Predicting benefit from anti-angiogenic agents in malignancyNature Reviews Cancer, 2006
- Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cellsJournal of Clinical Investigation, 2005
- Innovations and Challenges in Renal CancerClinical Cancer Research, 2004
- Disease-associated Bias in T Helper Type 1 (Th1)/Th2 CD4+ T Cell Responses Against MAGE-6 in HLA-DRB10401+ Patients With Renal Cell Carcinoma or MelanomaThe Journal of Experimental Medicine, 2002
- Differential Transcriptional Regulation of the Two Vascular Endothelial Growth Factor Receptor GenesJournal of Biological Chemistry, 1997
- Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cellsNature Medicine, 1996